HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christie M Ballantyne Selected Research

fenofibric acid

6/2014Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
7/2013Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
11/2012Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
8/2012Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
3/2012LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
12/2011Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
9/2011Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). [email protected].
2/2011Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
2/2009Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christie M Ballantyne Research Topics

Disease

191Atherosclerosis
12/2022 - 01/2002
150Cardiovascular Diseases (Cardiovascular Disease)
11/2022 - 08/2002
106Coronary Disease (Coronary Heart Disease)
11/2022 - 03/2003
62Inflammation (Inflammations)
11/2021 - 01/2002
60Heart Failure
06/2022 - 04/2010
44Stroke (Strokes)
01/2022 - 03/2002
39Hypertension (High Blood Pressure)
01/2022 - 03/2003
37Coronary Artery Disease (Coronary Atherosclerosis)
01/2021 - 11/2002
37Metabolic Syndrome (Dysmetabolic Syndrome X)
09/2020 - 11/2002
35Hypercholesterolemia
05/2022 - 01/2003
34Obesity
07/2021 - 06/2004
34Dyslipidemias (Dyslipidemia)
01/2021 - 11/2002
31Type 2 Diabetes Mellitus (MODY)
01/2022 - 06/2003
30Myocardial Infarction
03/2022 - 11/2008
30Hypertriglyceridemia
01/2022 - 08/2002
22Atherosclerotic Plaque (Atheroma)
09/2020 - 04/2006
21Atrial Fibrillation
01/2022 - 03/2008
21Insulin Resistance
01/2021 - 05/2004
20Diabetes Mellitus
01/2020 - 01/2006
19Weight Loss (Weight Reduction)
01/2022 - 06/2004
17Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/2022 - 11/2007
16Ischemic Stroke
11/2022 - 03/2003
16Acute Coronary Syndrome
01/2021 - 12/2009
14Peripheral Arterial Disease
01/2021 - 06/2010
10Infections
03/2021 - 03/2002
9Chronic Renal Insufficiency
03/2022 - 04/2011
9Fibrosis (Cirrhosis)
01/2022 - 11/2015
8Vascular Diseases (Vascular Disease)
01/2021 - 03/2002
8Hyperlipidemias (Hyperlipidemia)
10/2018 - 08/2002
7Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
01/2021 - 09/2015
7Carotid Artery Diseases
01/2019 - 11/2004
7Overweight
01/2017 - 07/2011
6Renal Insufficiency (Renal Failure)
01/2022 - 01/2009
6Unstable Angina
11/2021 - 11/2012
6Hyperglycemia
01/2021 - 03/2011
6Heart Diseases (Heart Disease)
01/2019 - 05/2006
5Kidney Diseases (Kidney Disease)
01/2022 - 01/2015
5Neoplasms (Cancer)
01/2022 - 02/2013
5Prediabetic State (Prediabetes)
01/2022 - 10/2014

Drug/Important Bio-Agent (IBA)

115LipidsIBA
01/2022 - 03/2002
112Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2022 - 01/2002
91LDL CholesterolIBA
12/2021 - 03/2002
74oxidized low density lipoproteinIBA
11/2022 - 04/2003
62Triglycerides (Triacylglycerol)IBA
11/2022 - 03/2002
57Biomarkers (Surrogate Marker)IBA
08/2022 - 08/2002
57HDL CholesterolIBA
01/2021 - 11/2002
54CholesterolIBA
08/2022 - 11/2002
53C-Reactive ProteinIBA
08/2022 - 07/2003
49Troponin T (Troponin T1)IBA
03/2022 - 04/2011
36Atorvastatin (Lipitor)FDA Link
08/2017 - 01/2003
32pro-brain natriuretic peptide (1-76)IBA
03/2022 - 02/2013
31Lipoproteins (Lipoprotein)IBA
11/2022 - 11/2002
31Brain Natriuretic Peptide (Natrecor)FDA Link
03/2022 - 04/2011
31Glucose (Dextrose)FDA LinkGeneric
01/2021 - 11/2002
28Ezetimibe (Zetia)FDA Link
12/2021 - 05/2003
27Rosuvastatin Calcium (Crestor)FDA Link
08/2017 - 01/2003
26LDL Lipoproteins (beta Lipoproteins)IBA
01/2021 - 03/2002
241-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA
08/2022 - 02/2004
24Simvastatin (Zocor)FDA LinkGeneric
12/2016 - 06/2003
23eicosapentaenoic acid ethyl esterIBA
01/2022 - 02/2013
23ApolipoproteinsIBA
01/2021 - 03/2002
19Lipoprotein(a)IBA
08/2022 - 09/2008
16Apolipoprotein A-I (Apolipoprotein A1)IBA
08/2017 - 03/2003
14Natriuretic PeptidesIBA
01/2021 - 04/2013
14HDL LipoproteinsIBA
01/2020 - 03/2002
13TroponinIBA
06/2022 - 04/2013
13AdiponectinIBA
08/2015 - 06/2004
128- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acidIBA
05/2022 - 09/2013
12Adenosine Triphosphate (ATP)IBA
02/2017 - 11/2002
12Niacin (Nicotinic Acid)FDA LinkGeneric
07/2011 - 11/2002
11Insulin (Novolin)FDA Link
01/2017 - 08/2002
10Galectin 3 (LGALS3)IBA
11/2021 - 01/2016
9Proteins (Proteins, Gene)FDA Link
01/2022 - 03/2012
9fenofibric acidFDA Link
06/2014 - 02/2009
8CalciumIBA
01/2022 - 09/2008
8Apolipoproteins E (ApoE)IBA
01/2021 - 03/2002
8IntegrinsIBA
01/2017 - 03/2002
8Fibric Acids (Fibrates)IBA
06/2014 - 11/2002
7Antihypertensive Agents (Antihypertensives)IBA
11/2022 - 06/2003
7Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2022 - 11/2008
7Pharmaceutical PreparationsIBA
12/2021 - 03/2003
7AlbuminsIBA
01/2020 - 04/2011
7EstersIBA
06/2019 - 07/2007
7Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA
04/2008 - 01/2002
6Troponin IIBA
06/2022 - 01/2019
6omega-Chloroacetophenone (Mace)IBA
08/2021 - 01/2004
6Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
01/2021 - 08/2006
6Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
01/2021 - 05/2005
6evolocumabIBA
09/2020 - 05/2014
6Apolipoproteins B (ApoB)IBA
01/2019 - 12/2008
6Blood Glucose (Blood Sugar)IBA
01/2019 - 03/2003
6Fibrinogen (Factor I)FDA Link
11/2017 - 07/2003
6Lactic Acid (Lactate)FDA LinkGeneric
02/2015 - 12/2008
6Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
02/2013 - 03/2002
5DNA (Deoxyribonucleic Acid)IBA
12/2022 - 04/2003
5Blood Proteins (Serum Proteins)IBA
01/2022 - 05/2008

Therapy/Procedure

116Therapeutics
11/2022 - 11/2002
8Secondary Prevention
01/2022 - 01/2004
8Coronary Artery Bypass (Coronary Artery Bypass Surgery)
01/2018 - 01/2011
5Drug Therapy (Chemotherapy)
01/2022 - 10/2009